// App-Quantinova.ai

TCT-460 : Multi-Center, Randomized Evaluation of the Elixir DESyne Novolimus Eluting Coronary Stent System with Biodegradable Polymer Compared to a Zotarolimus-Eluting Coronary Stent System: Final 5-Year Results from the EXCELLA BD Study

Researchers

Presenter

  • Stefan Verheye

Principal Investigators

  • Alexandre Abizaid

  • Roberto Botelho

  • Ricardo Costa

  • Luiz Fernando Tanajura

  • Katsuhisa Waseda

  • Lynn Morrison

  • Sara Toyloy

  • Peter J. Fitzgerald

  • Joachim Schofer

Medical Centers

  • Triangulo Heart Institute, Uberlandia, Brazil

  • Cardiovascular Institute Middelheim, Antwerp, Belgium

  • Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA

  • Elixir Medical, sunnyvale, California, United States

  • Hamburg University Cardiovascular Center and Department for percutaneous treatment of structural hea, Hamburg, Germany

  • ICU, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

  • Aichi Medical University, Owariasahi, Japan

Locations

  • Brazil

  • Japan

  • Germany

  • United States

  • Belgium

Companies

  • Elixir medical corpo

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

  • Restenosis

Biomarkers

  • N/A

Drug/Treatment

  • ZoMaxx

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved